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OBJECTIVES How effective and safe is rescue percutaneous transluminal coronary angioplasty [PTCA]
compared with primary PTCA, and is it cost effective?
BACKGROUND In acute myocardial infarction (AMI), primary PTCA has been shown to be beneficial in
terms of clinical outcome. In contrast, the value of rescue PTCA has not been established.
METHODS In a retrospective analysis, we compared the angiographic and clinical outcomes of 317
consecutive patients who had rescue PTCA ;90 min after failed thrombolysis and 442
patients treated with primary PTCA. An estimation of interventional costs was compared
with the strategies of primary and rescue PTCA or with the strategy of thrombolysis with
rescue PTCA, when indicated.
RESULTS Baseline characteristics between primary and rescue PTCA were comparable for most
variables. Treatment delay was longer for patients who had rescue PTCA: 240 min. versus
195 min. Coronary patency after PTCA was comparable: 90.2% for rescue PTCA and 91.4%
for primary PTCA (p 5 0.67, power 71.9%). In-hospital mortality rates were 4.7% and 6.6%,
respectively (p 5 0.37). Also, the other complications were fairly similar during the
in-hospital phase and during one-year follow-up. Predictors of death were age, infarct size,
localization of AMI, failed PTCA and left main stem occlusion. The estimated interventional
costs during one-year follow-up were $7,377 for primary PTCA and $8,246 for rescue
PTCA: difference $869 (11.7%).
CONCLUSIONS In this retrospective analysis of 759 patients with AMI, rescue angioplasty early after failed
thrombolysis seems to be as effective and safe as primary PTCA. In the present evaluation,
interventional costs of primary PTCA are less than those of rescue PTCA (p 5 0.0001). (J
Am Coll Cardiol 2000;36:51–8) © 2000 by the American College of Cardiology
Thrombolytic therapy and primary percutaneous translumi-
nal coronary angioplasty (PTCA) have been shown to be
beneficial in improving the angiographic and clinical out-
come of patients with acute myocardial infarction (AMI)
(1–4). The value of rescue PTCA early after failed throm-
bolysis is still controversial (5–8).
At the University Hospital of Maastricht, Maastricht,
The Netherlands, all three forms of these therapies have
been used since 1987. This retrospective analysis will show
the angiographic and clinical outcomes, including one-year
follow-up of rescue PTCA (n 5 317), which will be
compared with the accepted form of therapy: primary
PTCA (n 5 442). Over a 10-year period (from 1987 to
1997), all 759 patients had angioplasty in the acute phase of
their AMI.
METHODS
Patients. In our hospital, patients with clinical and elec-
trocardiographic (ECG) signs of AMI are treated with
thrombolytic therapy or PTCA if the chest pain lasts
$30 min. Initially, only patients up to 70 years of age had
such therapy in case treatment delay between chest pain and
intervention was ,4 h. At a later stage (since 1989), in
principle, no upper age criterion was used, and the treat-
ment delay increased to 6 h. In case of persistent pain and
ST segment elevation, patients with longer delays could also
undergo an intervention. Electrocardiographic criteria for
an intervention were ST segment elevation of at least 1 mm
in two or more extremity leads or ST segment elevation of
at least 2 mm in two or more precordial leads. During the
10-year period of the analysis, the number of patients at the
Maastricht Hospital with the final diagnosis AMI was
2,310. Of these patients, 901 (39%) were treated with
thrombolysis, 196 (21.8%) of whom underwent rescue
PTCA (9,10). In addition, 121 patients were referred from
five other hospitals for rescue PTCA (11,12). In the same
period, 287 of the patients with AMI (12.4%) who were
directly admitted to the Maastricht Hospital had primary
PTCA, and 155 patients were referred for such an inter-
vention. Two hundred forty-one of the patients who had
rescue PTCA were included in thrombolysis studies (11,13–
17), and 75 patients with primary PTCA were involved in
the LImburg Myocardial Infarction (LIMI) trial (11). The
reasons to decide for thrombolytic therapy or primary
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PTCA cannot accurately be described in this retrospective
analysis. Initially, the primary choice was thrombolysis,
unless a contraindication was present. For example, in 1987,
20 patients had rescue PTCA and only eight patients
underwent primary PTCA; in 1996, the numbers were
reversed to 72 patients and 111 patients, respectively.
Because of the excellent results of primary PTCA, as
reported in the published data, a gradual change in attitude
toward primary PTCA was observed. In addition, in 1996,
the LIMI study was under way (11). In our institution,
catheterization service is available on a 24-h basis.
Medication. Routine treatment of the AMI study group
was as follows: First, patients were given intravenous nitro-
glycerin and a bolus of 5,000 U heparin, followed by an
intravenous heparin drip titrated according to the activated
partial thromboplastin time (2 to 2.5 times the normal
value). Since 1988, patients were also pretreated with
aspirin. Patients treated with thrombolysis received one of
the following thrombolytic agents: streptokinase, alteplase,
anistreplase, reteplase, lanotaplase or saruplase, in the rec-
ommended dosages. None of the patients was treated with
a IIb/IIIa receptor blocker.
Cardiac catheterization. The median delay between ad-
mission and cardiac catheterization of the patients directly
admitted to the Maastricht Hospital was ;90 min. At that
time another 5,000 U heparin was given. Patients who were
involved in angiographic thrombolysis studies typically had
early catheterization at 60 to 90 min. In the other patients
who received thrombolytic therapy, angiography was per-
formed if ST segment resolution ($50%) was not observed
(18,19). Patients who had cardiac catheterization with
normal coronary perfusion grades after (apparently success-
ful) thrombolytic therapy were not considered to be candi-
dates for acute PTCA because of the results of the Throm-
bolysis In Myocardial Infarction (TIMI) II-A trial and the
European Cooperative Study (20,21). Angiographically
proven complete reperfusion (TIMI flow grade 3) after
thrombolytic therapy was observed in 50% to 70% of the
patients who were included in thrombolytic trials in which
early angiography was required (13–15). If thrombolytic
therapy failed or if primary PTCA was the therapy of
choice, coronary angioplasty was performed. In 5% of
patients, PTCA was also not performed if it appeared
unlikely that the patient would benefit from PTCA, because
only the occluded artery had perfused a small area. In
another 5% of patients, PTCA was not done because of
technical reasons or because of the complexity of the
coronary anatomy.
Successful PTCA was defined as complete restoration of
flow (TIMI flow grade 3) and residual stenosis ,50%
(qualitative assessment) 10 min after the last balloon infla-
tion. After successful PTCA, an additional bolus of 5,000 U
heparin and 300 mg intravenous aspirin were given.
During recent years, in an increasing number of patients,
a stent was implanted in case of insufficient or moderate
angiographic results. Initially, such patients were treated
with anticoagulant therapy. Since 1996, ticlopidine was
given instead of Coumadin in case of a stent implantation.
This drug was continued for four weeks in a dosage of
500 mg/day.
Clinical follow-up. Except for 11 patients who were lost to
follow-up, data are available for the first year after myocar-
dial infarction. Data on outcome during admission and
one-year follow-up will be given separately.
Interventional costs. Costs were calculated using esti-
mates of unit costs of the interventions during the first year
after AMI. The methods and calculated interventional costs
of Zijlstra et al. (22) were used. Admission duration was
similar for both groups. Medication at discharge and during
follow-up was also comparable. For this reason, these two
components were not introduced in the model. Also,
indirect costs were not taken into account.
Statistical analysis. Continuous variables are expressed as
the mean value 6 SD or as the median value (range),
depending on their distribution. The mean and median
values of two groups were compared using the Student
unpaired t test and the Mann-Whitney U test, respectively.
Categoric variables were compared using the chi-square
test, with a continuity correction in case of 2 3 2 tables.
Survival was depicted using the Kaplan-Meier curve, with
the log-rank test statistics for equality of survival distribu-
tion. A p value ,0.05 was considered to be statistically
significant.
The success rate in the primary PTCA group is 91.4%.
The aim of this study was to demonstrate that rescue PTCA
treatment has the same success rate or differs by no more
than 5% as compared with standard treatment. This differ-
ence of #5% is considered as clinically not relevant. On the
basis of the actual number of patients in both groups and a
p-value of 0.05 (one-sided), this study has a power of 71.9%
to reject the hypothesis that the difference is .5% (23).
RESULTS
Baseline data. The baseline clinical and angiographic char-
acteristics of the 759 patients who underwent rescue or
primary PTCA are presented in Table 1. Rescue PTCA was
performed in 317 patients (41.8%) and primary PTCA in
442 patients (58.2%). In total, 483 patients were primarily
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ECG 5 electrocardiographic
GUSTO 5 Global Use of Strategies To Open occluded
arteries trial
LCx 5 left circumflex coronary artery
LIMI 5 LImburg Myocardial Infarction trial
PACT 5 Plasminogen activator Angioplasty
Compatibility Trial
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis In Myocardial Infarction trial
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admitted to the Maastricht Hospital, whereas 276 patients
were referred from other hospitals (Table 2). Most baseline
data of the two types of treatment were comparable. Of the
known risk factors, diabetes was more frequent in the
primary PTCA group. More patients with a left circumflex
artery (LCx) (14.9% vs. 9.8%) and main stem lesions (1.1%
vs. 0.3%) had primary PTCA rather than rescue PTCA.
Note that the median delays between chest pain and PTCA
were acceptable (204 min for primary PTCA and 269 min
for rescue PTCA). Obviously, the delay between onset of
pain and PTCA was longer for patients who were trans-
ferred from other hospitals, especially for patients who
underwent rescue PTCA (Table 2).
Angiographic outcome. Before the intervention, 8 of the
759 patients had an open vessel and TIMI flow grade 2,
whereas all of the other 751 patients had a total occlusion
and TIMI flow grade 0 or 1. The angiographic results
showed that after the PTCA, 90.9% of patients had a patent
culprit vessel and good TIMI flow grade 3 (Table 3). In this
study, the effect size of rescue PTCA as compared with
primary PTCA is 21.2%, with a 90% confidence interval of
24.7% to 22.3%.
Success rate was independent of pretreatment with
thrombolytic agent. The complication rates of the invasive
procedure were also not different. In patients who under-
went rescue PTCA, somewhat more stents were used to
achieve an optimal result (12.9% vs. 8.2% for primary
PTCA). The number of stents implanted increased gradu-
ally over time. The first stent was implanted in 1993. In
1997, 29.2% of patients received a stent.
Clinical outcome. During the hospital period, the mortal-
ity rate was 4.7% for rescue PTCA and 6.6% for primary
PTCA (Table 4). Maximal aspartate aminotransferase was
highest in patients who had rescue PTCA. Reinfarction and
Table 1. Demographic and Angiographic Characteristics
Total Study Group
(n 5 759)
Rescue PTCA Group
(n 5 317)
Primary PTCA Group
(n 5 442) p Value
Age (yrs) 60.5 6 11.8 59.6 6 12.0 61.1 6 11.6 0.08
Males 558 (73.5%) 235 (74.0%) 323 (73.1%) 0.81
Anterior infarct 375 (49.4%) 151 (47.6%) 224 (50.7%) 0.07
History of infarct 174 (22.9%) 68 (21.5%) 106 (24.0%) 0.09
Known risk factors
Smoking 377 (49.7%) 158 (49.8%) 219 (49.5%) 0.07
Hypertension 226 (29.8%) 102 (32.2%) 124 (28.1%) 0.10
Diabetes 71 (9.4%) 25 (7.9%) 46 (10.4%) ,0.05
Hypercholesterolemia 193 (25.4%) 81 (25.6%) 112 (25.3%) 0.17
Positive family history 296 (39.0%) 131 (41.3%) 165 (37.3%) 0.69
Coronary arteries
Single-vessel disease 399 (52.6%) 163 (51.4%) 236 (53.6%) 0.87
Culprit lesion
LAD 360 (47.4%) 144 (45.4%) 216 (48.9%) ,0.05
RCA 271 (35.7%) 128 (40.4%) 143 (32.4%) ,0.05
LCx 97 (12.8%) 31 (9.8%) 66 (14.9%) ,0.05
LMCA 6 (0.8%) 1 (0.3%) 5 (1.1%) ,0.05
Graft 25 (3.3%) 13 (4.1%) 12 (2.7%) ,0.05
Data are presented as the mean value 6 SD or number (%) of patients.
LAD 5 left anterior descending coronary artery; LCx 5 circumflex artery; LMCA 5 left main coronary artery; PTCA 5 percutaneous transluminal coronary angioplasty;
RCA 5 right coronary artery.
Table 2. Delays in Minutes Between Pain and Intervention
Maastricht Hospital
(PTCA center)
Other Hospitals
(Non-PTCA Centers) p Value
Rescue PTCA
No. patients 196 121
Pain to admission 80 (0–660) 75 (0–480) 0.06
Pain to thrombolysis 118 (5–685) 110 (5–510) 0.19
Pain to arrival at Maastricht Hospital — 260 (50–645) —
Pain to catheterization 210 (40–930) 285 (80–695) ,0.001
Pain to PTCA 240 (60–945) 315 (95–710) ,0.01
Primary PTCA
No. patients 287 155
Pain to admission 90 (0–1,410) 60 (0–1,055) ,0.001
Pain to arrival at Maastricht Hospital — 170 (40–1,095) —
Pain to catheterization 180 (35–1,410) 200 (80–1,220) 0.06
Pain to PTCA 195 (50–1,430) 220 (105–1,245) 0.12
Data are presented as the median value in minutes (range).
PTCA 5 percutaneous transluminal coronary angioplasty.
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repeat intervention rates were comparable in both groups.
Because of pretreatment with a thrombolytic agent, more
blood transfusions were given in the rescue PTCA group
(p , 0.05). However, hospital stay was comparable. Causes
of death during the hospital stay are mentioned in Table 5.
The main reason for death was cardiogenic shock. Age,
infarct size, localization of myocardial infarction and failure
of PTCA were predictors of long-term mortality (Table 6).
In this cohort of patients, the few patients with acute main
stem occlusions had a poor outcome (five of six patients
died).
After discharge, one-year mortality was slightly higher in
the primary PTCA group than in the rescue PTCA group
(3.7% vs. 2.7%) (p 5 0.63) (Fig. 1). However, during the
complete one-year follow-up, no statistical differences were
found between the two groups (p 5 0.24). Somewhat more
patients who had primary PTCA had heart failure (p 5
0.39) (Table 7). In 77 patients, a stent was implanted. As
compared with the patients who had no stents, no differ-
ences during the one-year follow-up were observed for
reinfarction, presence of angina, repeat PTCA, coronary
artery bypass graft surgery or mortality. These findings were
consistent for both primary PTCA and rescue PTCA.
Angioplasty failed in 69 patients. Their clinical outcome
was clearly worse compared with patients having successful
angioplasty and independent of treatment allocation (Table
8).
Interventional costs. Total interventional costs of rescue
PTCA during the first year after AMI were $869 (11.7%)
more expensive than those of primary PTCA (p 5 0.0001)
(Table 9).
DISCUSSION
Mortality and patency. Is rescue PTCA as safe and effec-
tive as the accepted form of therapy: primary PTCA? This
series of 759 patients treated with PTCA in the acute phase
of AMI is the largest (single-center) cohort published so far.
The results of this analysis indicate that the aggressive
approach of our institution to reopen the culprit coronary
artery promptly results in comparable patency rates (power
71.9%) and an acceptable overall in-hospital mortality rate
(5.8%), as well as one-year mortality rate (9.1%). At least in
this analysis, the outcome of rescue PTCA is fairly similar to
that of primary PTCA. It is likely that the short delay
between the start of thrombolytic therapy and rescue PTCA
(690 min) is the most important factor explaining this. The
outcomes of the few and small-sized rescue PTCA studies
that have been previously reported were usually worse. In
the group presented here, the rescue PTCA group repre-
sented those patients in whom thrombolytic therapy failed.
The mortality of the patients who had primary PTCA is
clearly higher than that in the initial randomized trials of
Grines et al. (2), Zijlstra et al. (3) and Gibbons et al. (4). In
contrast, in the larger sized, “more real world” Global Use of
Table 3. Angiographic Results (Qualitative Assessment)
Total Study Group
(n 5 759)
Rescue PTCA Group
(n 5 317)
Primary PTCA Group
(n 5 442) p Value
Diameter stenosis before PTCA
Median value (range) 100 (70–100) 100 (80–100) 100 (70–100) 0.90
Successful PTCA 690 (90.9%) 286 (90.2%) 404 (91.4%) 0.67
Diameter stenosis after PTCA
Median (range) 20 (0–100) 20 (0–100) 20 (0–100) 0.89
Stent 77 (10.2%) 41 (12.9%) 36 (8.2%) ,0.05
Data are presented as the number (%) of patients or median (range).
PTCA 5 percutaneous transluminal coronary angioplasty.
Table 4. Clinical Outcome During the Hospital Period
Total Study Group
(n 5 759)
Rescue PTCA Group
(n 5 317)
Primary PTCA Group
(n 5 442) p Value
Death 44 (5.8%) 15 (4.7%) 29 (6.6%) 0.37
Reinfarction 45 (5.9%) 16 (5.1%) 29 (6.6%) 0.47
Repeat PTCA 68 (9.0%) 29 (9.2%) 39 (8.8%) 0.99
CABG 32 (4.2%) 12 (3.8%) 20 (4.5%) 0.75
Any of the above 135 (17.8%) 53 (16.7%) 82 (18.6%) 0.58
Recurrent angina 100 (13.2%) 44 (13.9%) 56 (12.7%) 0.70
CVA 6 (0.8%) 3 (0.9%) 3 (0.7%) 1.00
Blood transfusion 19 (2.5%) 13 (4.1%) 6 (1.4%) ,0.05
Maximal ASAT 255 (17–2,000) 312 (43–1,537) 215 (17–2,000) ,0.01
Ejection fraction* (%) 46 6 11.8 45.4 6 11.4 46 6 12.1 0.54
Hospital stay (days) 8.1 6 8.6 8.2 6 7.5 8.1 6 9.7 0.46
*By echocardiography.
Data are presented as the number (%) of patients, mean value 6 SD or median value (range).
ASAT 5 aspartate aminotransferase; CABG 5 coronary artery bypass graft surgery; CVA 5 cerebrovascular accident; PTCA 5 percutaneous transluminal coronary
angioplasty.
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Strategies To Open occluded arteries (GUSTO) IIb study
(24), patients who had primary PTCA had an in-hospital
mortality rate of 5.7%, more or less identical to that in our
group of patients.
In the present analysis, no significant in-hospital and
one-year mortality differences were observed between rescue
PTCA and primary PTCA. However, one has to realize
that a comparison between these two groups has limitations,
as will be discussed in the last paragraph. In our previous
study, we reported on the poor outcome of patients with
failed angioplasty (25). This finding is well known for failed
rescue PTCA. Table 8 shows that failed primary PTCA
carries comparable risks. More patients in the latter group
had bypass surgery, which, in contrast to rescue PTCA,
could be done early because of the normal fibrinolytic state.
Patients with successful thrombolysis were not included in
the angiographic and clinical part of the analysis. The
outcome of patients with successful thrombolysis is usually
excellent (9–12), indicating that the clinical outcome of
both groups (patients with successful thrombolysis and
patients with rescue PTCA) must be favorable. None of the
patients had IIb/IIIa receptor blocker treatment. The out-
come of the rescue PTCA group, as well as of the primary
PTCA group, is likely to improve with this type of therapy
(26–28).
In the randomized LIMI study, a first attempt was made
to compare three treatment strategies in patients admitted
to non-PTCA hospitals (11): 1) thrombolytic therapy and
local routine treatment; 2) thrombolytic therapy, followed
by transfer to the PTCA center where rescue PTCA was
performed in case of impaired coronary flow; and 3) transfer
for primary PTCA. In that study, no important differences
were detected in the angiographic success rates between
patients randomized to thrombolytic therapy and rescue
PTCA, when indicated, and patients randomized to pri-
mary PTCA (90% vs. 97%). The total number of patients in
that study (n 5 224) was too low to draw firm conclusions
on the efficacy of the three strategies. The results of the
Prague study were presented during the European Congress
of Cardiology in Barcelona in 1999 (29). That study had an
identical setup to that of the LIMI trial. Their findings were
that mortality rate in the thrombolysis-only group was 15%,
as compared with 12% in the rescue PTCA group and 7%
in the primary PTCA group. It is unclear, so far, why such
high mortality rates were found in the first two groups.
Recently, the data of the Plasminogen activator Angioplasty
Compatibility Trial (PACT) were presented (30). In that
trial, patients were treated with a bolus of 50 mg alteplase or
with placebo, followed by immediate angiography. In pa-
tients with TIMI flow grade 3, an additional bolus of 50 mg
alteplase was given, and these patients were treated medi-
cally. In patients with impaired flow, immediate PTCA was
performed. In that study, the angiographic and clinical
outcomes in patients with primary and rescue PTCA were
similar: the angiographic success rates were 93% and 95%,
whereas the mortality rates were 3.4% and 3.0%, respec-
tively.
Rescue PTCA and primary PTCA have been used
routinely in our hospital for .10 years. Previously, we
published the outcome of the initial 176 patients who
Figure 1. Kaplan-Meier one-year survival curves for patients having
primary PTCA (dashed line) and rescue PTCA (wavy line). The
differences between the two groups are statistically not different (p 5 0.24).
Table 5. Causes of Death During the Hospital Period
Total Deaths
(n 5 44)
Cardiogenic shock 16 (36.4%)
VT/VF 9 (20.5%)
Reinfarction 4 (9.1%)
Bleeding 4 (9.1%)
CVA 3 (6.8%)
Respiratory insufficiency 3 (6.8%)
Sepsis 2 (4.6%)
Tamponade 1 (2.3%)
Other 2 (4.6%)
Data are presented as the number (%) of patients.
CVA 5 cerebrovascular accident; VF 5 ventricular fibrillation; VT 5 ventricular
tachycardia.
Table 6. Predictive Factors of One-Year Mortality in 759
Patients Who Underwent Early Percutaneous Transluminal
Coronary Angioplasty: Univariate Analysis
Deaths
(n 5 67)
Survivors
(n 5 681) p Value
Males 46 (68.7%) 506 (74.3%) 0.39
Age (years) 68.7 6 11.0 59.7 6 11.5 ,0.001
Thrombolysis 23 (34.3%) 287 (42.1%) 0.27
Failed PTCA 17 (25.4%) 52 (7.6%) ,0.001
Myocardial infarction
Anterior 41 (61.2%) 330 (48.5%) 0.06
Inferior 28 (41.8%) 349 (51.3%) 0.18
Maximal ASAT 334 (52–2,000) 253 (17–1,555) 0.07
Culprit lesion
LAD 32 (47.8%) 324 (47.6%) ,0.001
RCA 19 (28.4%) 246 (36.1%) ,0.001
LCx 5 (7.5%) 91 (13.4%) ,0.001
LMCA 5 (7.5%) 1 (0.2%) ,0.001
Graft 6 (9.0%) 19 (2.8%) ,0.001
Data are presented as the number (%) of patients, mean value 6 SD or median value
(range).
ASAT 5 aspartate aminotransferase; other abbreviations as in Table 2.
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underwent early angioplasty (25). This retrospective analysis
already suggested that the angiographic and clinical out-
comes of primary and rescue PTCA in our hospital were
comparable. The present study confirmed this in a much
larger patient population. In a study of 133 patients,
McKendall et al. (31) found no significant advantage of
rescue PTCA as compared with thrombolytic treatment
only. They suggested that the moderate success rate (82%)
of the rescue PTCA procedure and the reocclusion rates
(6%) of their study were responsible for the rather high
mortality (12%). In that study, the delay between onset of
pain and intervention was short (180 6 54 min). In
contrast, in the present study, procedural success of the
rescue PTCA procedure is good (90.9%), and the reinfarc-
tion rate is acceptable (5.1%). This might partially explain
the differences between McKendall’s and our findings.
Delays and need for angiography. When comparing the
delays (pain to start of PTCA) of patients admitted to our
hospital and patients sent from other hospitals, we found
that the median difference was 75 min in the rescue PTCA
group; in the primary PTCA group, this difference was only
25 min. Frequently, the decision to transfer patients requires
much more time (Table 2). The main reason is that, not
uncommonly, the result of thrombolytic therapy is awaited.
In case of no reperfusion, the patient will be transferred. In
patients who are candidates for primary or rescue PTCA,
the shortest possible delay between chest pain and starting
the procedure should be achieved. The delay can only be
short if logistics are optimal: the catheterization team has to
be available on a 24-h basis. In our setting, outside office
hours, the team is immediately called when a patient with
an extensive AMI is admitted to the Maastricht Hospital.
This approach differs importantly from that of many other
centers, where the decision to catheterize after failed throm-
bolytic therapy is frequently postponed and only done if the
condition of the patient deteriorates further. This probably
explains why, in such a setting, the outcome is usually poor.
Noninvasive reperfusion criteria can be used with reason-
able accuracy before starting the invasive procedure to
determine whether angiography is still needed (18,19). In a
subgroup analysis, Oude Ophuis et al. (12) found that 66
patients (40%) who were treated with thrombolytic therapy
and referred from another hospital showed these noninva-
sive reperfusion signs. None of these 66 patients had early
catheterization. Nearly all patients immediately returned to
the referring hospital and none of them died in the hospital,
indicating that such an approach is safe. In case of no or
questionable reperfusion (based on the noninvasive criteria),
we performed angiography immediately, followed by rescue
PTCA in case of inadequate flow.
Costs. In this analysis, only the unit costs of the interven-
tions are taken into account. The reason is that no signifi-
cant differences were observed in admission duration and
medication. Our analysis shows that primary PTCA is less
expensive than rescue PTCA. However, one has to keep in
mind that the patients in the rescue PTCA group were only
selected because of failed thrombolytic therapy. If the total
thrombolysis group were analyzed, interventional costs
would be lower. First, in our hospital, patients with clear
ECG signs of reperfusion usually will not undergo early
angiography. Second, in the remaining patients in whom
early acute angiography is performed, one-third of the them
Table 7. Clinical Outcome From Discharge to One Year
Total Study Group Rescue PTCA Group Primary PTCA Group p Value
All patients 759 317 442
Patients discharged alive 715 302 413
Follow-up* 704 (100%) 296 (100%) 408 (100%)
Death 23 (3.3%) 8 (2.7%) 15 (3.7%) 0.63
Reinfarction 14 (2.0%) 6 (2.0%) 8 (2.0%) 1.00
Repeat PTCA 43 (6.1%) 22 (7.4%) 21 (5.1%) 0.27
CABG 26 (3.7%) 11 (3.7%) 15 (3.7%) 1.00
Heart failure 29 (4.1%) 8 (2.7%) 21 (5.1%) 0.39
Any of the above 111 (15.8%) 43 (14.2%) 68 (16.7%) 0.55
Recurrent angina 127 (18.0%) 50 (16.9%) 77 (18.6%) 0.60
*Eleven patients (1.5%) were lost to follow-up.
Data are presented as the number (%) of patients.
Abbreviations as in Table 4.
Table 8. One-Year Clinical Outcome: Comparison Between
Patients With Failed and Successful Angioplasty
Primary PTCA
p ValueFailure Success
All patients 38 (100%) 404 (100%)
Death 10 (26.3%) 34 (8.4%) 0.001
Reinfarction 4 (10.5%) 25 (6.1%) 0.51
Angina 10 (26.3%) 46 (11.4%) 0.02
Repeat PTCA 6 (15.8%) 33 (8.7%) 0.21
CABG 8 (21.1%) 12 (3.0%) 0.0001
Rescue PTCA
p ValueFailure Success
All patients 31 (100%) 286 (100%)
Death 7 (22.6%) 16 (5.6%) 0.002
Reinfarction 4 (12.9%) 12 (4.2%) 0.99
Angina 9 (29.0%) 35 (12.2%) 0.18
Repeat PTCA 2 (6.5%) 27 (9.4%) 0.81
CABG 2 (6.5%) 10 (3.5%) 0.76
Data are presented as the number (%) of patients.
Abbreviations as in Table 4.
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will have TIMI flow grade 3; therefore, no early interven-
tion will be performed (18). The price to pay for this
relatively conservative approach is that at a later stage, more
subacute interventions, as compared with primary PTCA,
must be performed because of reischemia. However, the
advantage is that these procedures usually can be scheduled.
Study limitations. This analysis is nonrandomized and
retrospective in nature, and it is a single-center experience.
Patients who have primary versus rescue PTCA are not
completely similar. Primary PTCA usually is preferred over
thrombolytic agents in case ECG findings suggest extensive
ischemia or a poor hemodynamic state. Such an approach
was also used in our patients. For example, this resulted in
an overrepresentation of main stem occlusions in the pri-
mary PTCA group (five of six patients). All five patients
died in the hospital. In addition, baseline data showed that
more patients had LCx occlusion in the primary PTCA
group (p , 0.05). This is most likely explained by the
absence of characteristic ECG changes of an occlusion in
that location. Patients with true posterior AMI not uncom-
monly show only precordial ST segment depression with no
or minimal ST segment elevation. These ECG changes and
the persistence of pain are usually the reason to perform
angiography without thrombolytic pretreatment to differ-
entiate between the diagnosis of unstable angina and AMI.
When during angiography it becomes apparent that the
LCx is occluded, primary PTCA will be done. This group
of patients with LCx lesions usually has a reasonably good
prognosis.
The need for rescue PTCA after failed thrombolysis is
more obvious in patients with an extensive AMI than in
those with a small AMI. In addition, of all patients who had
thrombolysis, the patients who have rescue PTCA represent
the worst group because of pharmacologic treatment failure.
Enzymatic infarct size was higher in the rescue PTCA
group than in the primary PTCA group. Either the area at
risk was larger in the rescue PTCA group or the treatment
with thrombolytic therapy and rescue PTCA resulted in
more muscle loss. Also, the longer delay between onset of
pain and PTCA in the rescue group will have influenced the
amount of muscle loss.
The calculation of unit costs was based on an estimation
of the percentage of interventions and prices. Other costs
for medication and admission duration were not taken into
account, because these were comparable. Indirect costs have
not been calculated.
Conclusions. Although this retrospective study has several
limitations, the results suggest that from a clinical perspec-
tive, rescue PTCA after failed thrombolysis is a good
alternative to the accepted form of therapy: primary PTCA.
This procedure is safe and effective, but is somewhat more
expensive. The costs found may differ in a prospective study
and will also differ locally.
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